BREEZOMETER
20.2.2020 18:37:08 CET | Business Wire | Press release
BreezoMeter, leading provider of air quality data, has won sought after funding & endorsement from the EU’s Horizon 2020 Research & Innovation programme. The research will focus on understanding air quality health impact & improving forecast methods.
Horizon 2020 is the biggest EU Research & Innovation programme, with nearly €80 billion of funding over 7 years. It’s the financial instrument of the ‘Innovation Union’, designed to secure Europe’s future global competitiveness. The grant is awarded to those demonstrating world-class science and industrial leadership.
The prestigious grant was awarded for AQ-Watch (Air Quality: Worldwide Analysis & Forecasting of Atmospheric Composition for Health). The project received funding from the European Union’s Horizon 2020 research and innovation programme under EC grant agreement No 870301.
The project is led by the Max Planck Institute for Meteorology, Hamburg, Germany - and coordinated by Prof. Dr. Guy Brasseur and Dr. Gabriela Adler, BreezoMeter Chief Scientist with a PhD in Atmospheric Chemistry & Climatology.
By providing air quality information at a resolution and granularity of up to 5 meters, BreezoMeter brings unique expertise. BreezoMeter will also partner with several leading institutions around the world in 10 different countries.
Ran Korber, CEO at BreezoMeter said, “We’re excited to win Horizon 2020. This endorsement from the European Commission proves the strong science behind what we do and helps in our quest to improve access to actionable air quality information & improve the health of billions worldwide.”
Professor Guy Brasseur, project coordinator, said, “We are very pleased to cooperate with BreezoMeter in AQ-Watch. As the world leader for accurate air quality data, BreezoMeter’s expertise will enable AQ-Watch to reach unprecedented levels of services to potential customers anywhere in the world.”
Horizon 2020 received over 120,000 eligible applications . BreezoMeter’s selection is a significant validation of their technology, enabling them to work with leading institutions to advance analysis and forecasting of air quality.
BreezoMeter:
BreezoMeter is the leading provider of street-level and real-time air quality information, including air pollution, pollen and active fires data. Their free Android and iOS apps help individuals protect themselves from harmful air exposure. Their APIs enable businesses to increase sales & product engagement. BreezoMeter is already integrated by leading brands across healthcare, smart home, automotive, and cosmetic industries.
AQ-Watch:
AQ-Watch (Air Quality: Worldwide Analysis & Forecasting of Atmospheric Composition for Health) is a project funded by the European Commission (Grant Agreement 870301) under the Horizon 2020 Programme. AQ-Watch solutions aim at improving air quality management and forecast, and thus contribute to a better public health and optimized services from the energy sector. A toolbox made of seven innovative products and services will be developed using state-of-the-art atmospheric models and European Copernicus datasets, and will be tested in three regions of the world: in Chile, in Colorado (USA) and in Beijing-Tianjin-Hebei area (China). The AQ-Watch consortium includes 12 top level institutes, applied science organizations and business-oriented partners from 10 countries.
Website: www.aq-watch.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005742/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom